Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Transmucosal gastric leak induced by proton pump inhibitors.

Murray LJ, Gabello M, Rudolph DS, Farrell CP, Morgan M, Martin AP, Underwood JC, Valenzano MC, Mullin JM.

Dig Dis Sci. 2009 Jul;54(7):1408-17. doi: 10.1007/s10620-008-0528-z. Epub 2008 Nov 18.

PMID:
19015985
2.

Omeprazole induces gastric permeability to digoxin.

Gabello M, Valenzano MC, Barr M, Zurbach P, Mullin JM.

Dig Dis Sci. 2010 May;55(5):1255-63. doi: 10.1007/s10620-009-0851-z. Epub 2009 Jun 10.

PMID:
19513837
3.

Omeprazole induces gastric transmucosal permeability to the peptide bradykinin.

Gabello M, Valenzano MC, Zurbach EP, Mullin JM.

World J Gastroenterol. 2010 Mar 7;16(9):1097-103.

4.

The anti-secretory and anti-ulcer activities of esomeprazole in comparison with omeprazole in the stomach of rats and rabbits.

Bastaki SM, Chandranath IS, Singh J.

Mol Cell Biochem. 2008 Feb;309(1-2):167-75. Epub 2007 Nov 28.

PMID:
18044010
5.

Esomeprazole induces upper gastrointestinal tract transmucosal permeability increase.

Mullin JM, Valenzano MC, Whitby M, Lurie D, Schmidt JD, Jain V, Tully O, Kearney K, Lazowick D, Mercogliano G, Thornton JJ.

Aliment Pharmacol Ther. 2008 Dec 1;28(11-12):1317-25. doi: 10.1111/j.1365-2036.2008.03824.x. Epub 2008 Aug 4.

6.

Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo.

Kwon D, Chae JB, Park CW, Kim YS, Lee SM, Kim EJ, Huh IH, Kim DY, Cho KD.

Arzneimittelforschung. 2001;51(3):204-13.

PMID:
11304936
7.

Gastroprotective activity of the novel proton pump inhibitor lansoprazole in the rat.

Morini G, Grandi D, Arcari ML, Bertaccini G.

Gen Pharmacol. 1995 Sep;26(5):1021-5.

PMID:
7557244
8.

Omeprazole increases permeability across isolated rat gastric mucosa pre-treated with an acid secretagogue.

Hopkins AM, McDonnell C, Breslin NP, O'Morain CA, Baird AW.

J Pharm Pharmacol. 2002 Mar;54(3):341-7.

PMID:
11902800
9.

Lansoprazole induces mucosal protection through gastrin receptor-dependent up-regulation of cyclooxygenase-2 in rats.

Tsuji S, Sun WH, Tsujii M, Kawai N, Kimura A, Kakiuchi Y, Yasumaru S, Komori M, Murata H, Sasaki Y, Kawano S, Hori M.

J Pharmacol Exp Ther. 2002 Dec;303(3):1301-8.

10.

Omeprazole-Mg 20.6 mg is superior to lansoprazole 15 mg for control of gastric acid: a comparison of over-the-counter doses of proton pump inhibitors.

Miner PB Jr, McKean LA, Gibb RD, Erasala GN, Ramsey DL, McRorie JW.

Aliment Pharmacol Ther. 2010 Apr;31(8):846-51. doi: 10.1111/j.1365-2036.2010.04258.x. Epub 2010 Feb 8.

11.

Effect of proton pump inhibitors on the secretion of bicarbonates and pepsinogen induced by chemical stimulation of the gastric mucosa.

Zolotarev VA, Khropycheva RP.

Bull Exp Biol Med. 2013 Feb;154(4):415-8. English, Russian.

PMID:
23486568
12.

Current status of acid pump antagonists (reversible PPIs).

Wurst W, Hartmann M.

Yale J Biol Med. 1996 May-Jun;69(3):233-43.

13.

Safety profile of the proton-pump inhibitors.

Reilly JP.

Am J Health Syst Pharm. 1999 Dec 1;56(23 Suppl 4):S11-7. Review.

PMID:
10597119
14.

A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals.

Hori Y, Matsukawa J, Takeuchi T, Nishida H, Kajino M, Inatomi N.

J Pharmacol Exp Ther. 2011 Jun;337(3):797-804. doi: 10.1124/jpet.111.179556. Epub 2011 Mar 16.

15.

Gastric antisecretory activity of lansoprazole in different experimental models: comparison with omeprazole.

Coruzzi G, Adami M, Bertaccini G.

Gen Pharmacol. 1995 Sep;26(5):1027-32.

PMID:
7557245
16.

Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats.

Katashima M, Yamamoto K, Sugiura M, Sawada Y, Iga T.

Drug Metab Dispos. 1995 Jul;23(7):718-23.

PMID:
7587960
17.

A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.

Frelinger AL 3rd, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Brooks JK, Bhatt DL, Michelson AD.

J Am Coll Cardiol. 2012 Apr 3;59(14):1304-11. doi: 10.1016/j.jacc.2011.12.024. Erratum in: J Am Coll Cardiol. 2012 Aug 7;60(6):566-7.

18.
19.

Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH.

Kirchheiner J, Glatt S, Fuhr U, Klotz U, Meineke I, Seufferlein T, Brockmöller J.

Eur J Clin Pharmacol. 2009 Jan;65(1):19-31. doi: 10.1007/s00228-008-0576-5. Epub 2008 Oct 17. Review.

PMID:
18925391
20.

Review of esomeprazole in the treatment of acid disorders.

Johnson DA.

Expert Opin Pharmacother. 2003 Feb;4(2):253-64. Review.

PMID:
12562316

Supplemental Content

Support Center